4-(dioleylmethyl)-1-methylpyridinium chloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-(dioleylmethyl)-1-methylpyridinium chloride
• 英文别名: N-methyl-4(dioleyl)methylpyridiniumchloride；4-[(9Z,28Z)-heptatriaconta-9,28-dien-19-yl]-1-methylpyridin-1-ium;chloride
• 化学式: C₄₃H₇₈N*Cl
• 分子量: 644.552
• InChiKey: FQKXELHZMFODBN-YIQDKWKASA-M

计算性质

• 辛醇/水分配系数(LogP)：
  11.45
• 重原子数：
  45
• 可旋转键数：
  33
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  3.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  油醇 在 Dowex (Cl^- form) 、 三乙胺 、 sodium iodide 、 lithium diisopropyl amide 作用下， 以 乙醚 、 正己烷 、 二氯甲烷 、 丙酮 为溶剂， 反应 3.0h， 生成 4-(dioleylmethyl)-1-methylpyridinium chloride
  参考文献：
  名称：

  Synthesis of Pyridinium Amphiphiles Used for Transfection and Some Characteristics of Amphiphile/DNA Complex Formation

  摘要：

  DOI：

  10.1002/(sici)1099-0690(200002)2000:4<665::aid-ejoc665>3.0.co;2-a

文献信息

• Particles with improved solubilization capacity
  申请人：——

  公开号：US20030022242A1

  公开（公告）日：2003-01-30

  A particle is disclosed that comprises a first volume of hydrophobe-rich material with tunable dissolution and solubilization characteristics and a distinct second volume of nanostructured nonlamellar liquid crystalline material, said second volume containing said first domain and being capable of being in equilibrium with said first volume. Preferably, the nanostructured nonlamellar liquid crystalline material is capable of being in equilibrium with a polar solvent or a water-immiscible solvent or both.

  揭示了一种颗粒，包括具有可调溶解和溶解特性的第一体积的疏水基质材料和独特的第二体积的纳米结构非层状液晶材料，所述第二体积包含所述第一领域，并能够与所述第一体积处于平衡状态。优选，所述纳米结构非层状液晶材料能够与极性溶剂或水不相溶溶剂或两者同时处于平衡状态。
• COATED PARTICLES, METHODS OF MAKING AND USING
  申请人：——

  公开号：US20040201117A1

  公开（公告）日：2004-10-14

  A particle coated with a nonlamellar material such as a nonlamellar crystalline material, a nonlamellar amorphous material, or a nonlamellar semi-crystalline material includes an internal matrix core having at least one a nanostructured liquid phase, or at least on nanostructured liquid crystalline phase or a combination of the two is used for the delivery of active agents such as pharmaceuticals, nutrients, pesticides, etc. The coated particle can be fabricated by a variety of different techniques where the exterior coating is a nonlamellar material such as a nonlamellar crystalline material, a nonlamellar amorphous material, or a nonlamellar semi-crystalline material

  涂覆有非层状材料（如非层状晶体材料、非层状非晶态材料或非层状半晶态材料）的粒子，包括具有至少一个纳米结构液相或至少一个纳米结构液晶相或两者的组合的内部基质核心，用于传递活性剂，如药物、营养素、杀虫剂等。涂覆的粒子可以通过各种不同的技术制造，其中外部涂层是非层状材料，如非层状晶体材料、非层状非晶态材料或非层状半晶态材料。
• Coated particles, methods of making and using
  申请人：——

  公开号：US20030108743A1

  公开（公告）日：2003-06-12

  A particle coated with a nonlamellar material such as a nonlamellar crystalline material, a nonlamellar amorphous material, or a nonlamellar semi-crystalline material includes an internal matrix core having at least one a nanostructured liquid phase, or at least on nanostructured liquid crystalline phase or a combination of the two is used for the delivery of active agents such as pharmaceuticals, nutrients, pesticides, etc. The coated particle can be fabricated by a variety of different techniques where the exterior coating is a nonlamellar material such as a nonlamellar crystalline material, a nonlamellar amorphous material, or a nonlamellar semi-crystalline material

  涂覆有非层状材料的颗粒，例如非层状晶体材料、非层状非晶材料或非层状半晶材料，包括至少一个纳米结构液相的内部基质核心，或至少一个纳米结构液晶相或两者的组合，用于传递活性物质，如药物、营养素、杀虫剂等。涂覆的颗粒可以通过各种不同的技术制造，其中外部涂层是非层状材料，例如非层状晶体材料、非层状非晶材料或非层状半晶材料。
• Drug-delivery vehicles based on reversed liquid crystalline phase materials
  申请人：Lyotropic Therapeutics, Inc.

  公开号：EP2264126A2

  公开（公告）日：2010-12-22

  Uncoated particles of reversed cubic phase or reversed hexagonal phase material containing an active disposed within are provided. The uncoated particles have an ionic charge that is sufficient to stabilize them in dispersion in a liquid, e.g. a polar solvent. The active that is disposed within the particles may be, for example, a pharmaceutical or nutriceutical compound. The invention also contemplates drug formulations containing reversed hexagonal and reversed cubic phases that can be applied to significantly increase the duration of action of the drug and/or provide the same duration and efficiency at a significantly lower dose.

  提供了反转立方相或反转六方相材料的无涂层颗粒，其中含有活性物质。未涂层颗粒带有离子电荷，足以使其在液体（如极性溶剂）中分散稳定。例如，置于颗粒内的活性物质可以是药物或营养化合物。本发明还考虑了含有反向六方相和反向立方相的药物制剂，可用于显著延长药物的作用时间和/或以明显较低的剂量提供相同的作用时间和效率。
• Treatment using dantrolene
  申请人：Lyotropic Therapeutics, Inc.

  公开号：US10314822B2

  公开（公告）日：2019-06-11

  Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.

  与目前已获批准并在市场上销售的用于治疗恶性高热（MH）危及麻醉危机的丹曲林相比，我们提供的小剂量、安全注射型丹曲林制剂具有显著优势。一旦丹曲林可以立即用于触发恶性高热的患者，麻醉医师就能在这种复杂多变的危机中专注于患者生理状态的管理，而不是费力费时的解救剂重组过程。丹曲林的注射剂量小、安全性高，与目前使用的预防和治疗泵头及其他因先天性或外伤引起的血流改变导致的神经、认知和运动功能障碍的方法相比具有显著优势，包括在涉及 CPB 或相关程序的手术过程中发生的泵头及其他因先天性或疾病引起的非正常体温事件中发生的泵头及其他神经、认知和运动功能障碍。